MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Henagliflozin

Search medical newsFind research, conditions and clinical updates
  • Home
  • Henagliflozin
Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects

Posted by By MedXY 09/18/2025
A randomized placebo-controlled trial demonstrates that henagliflozin improves telomere length and multiple aging biomarkers in patients with type 2 diabetes, suggesting potential anti-aging benefits beyond glucose control.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Exercise as a Cognitive Buffer in Midlife Women: Insights into Domain-Specific Effects and Modality Differences
  • Empowering Safer Mobility Behaviors to Prevent Falls in Parkinson’s Disease: Insights from Clinicians and Researchers
  • Eating Difficulty as a Marker for Broader Functional Vulnerability and Cognitive Decline in Older Adults: Insights from Four Large Ageing Cohorts
  • Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression
  • Longitudinal Executive Function Development in Very Preterm Children: Persistent Challenges into Adolescence
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top